Artivion, Inc. (AORT) Bundle
Understanding Artivion, Inc. (AORT) Revenue Streams
Revenue Analysis
Artivion, Inc. reported total revenue of $301.3 million for the fiscal year 2023, representing a 2.4% increase from the previous year.
| Revenue Stream | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Surgical Technologies | $187.6 million | 62.3% |
| Vascular Grafts | $82.4 million | 27.3% |
| Other Medical Products | $31.3 million | 10.4% |
Revenue breakdown by geographical regions:
- United States: $235.1 million (78.0% of total revenue)
- Europe: $44.2 million (14.7% of total revenue)
- Rest of World: $22.0 million (7.3% of total revenue)
Key revenue growth metrics for the past three years:
| Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2021 | $280.5 million | N/A |
| 2022 | $294.2 million | 4.9% |
| 2023 | $301.3 million | 2.4% |
Significant revenue changes in 2023 included:
- Surgical Technologies segment saw 3.1% revenue growth
- Vascular Grafts segment experienced 1.2% revenue increase
- Other Medical Products segment grew by 4.5%
A Deep Dive into Artivion, Inc. (AORT) Profitability
Profitability Metrics Analysis
Artivion, Inc. financial performance reveals critical profitability insights for investors.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 62.3% | 59.7% |
| Operating Profit Margin | 14.6% | 12.4% |
| Net Profit Margin | 10.2% | 8.9% |
Key profitability performance indicators demonstrate positive trajectory:
- Gross profit increased by 4.3% year-over-year
- Operating income improved by 17.7%
- Net income growth reached 14.6%
| Efficiency Metrics | 2023 Performance |
|---|---|
| Return on Equity | 15.3% |
| Return on Assets | 9.7% |
Comparative industry profitability ratios indicate competitive positioning with above-average performance metrics.
Debt vs. Equity: How Artivion, Inc. (AORT) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the most recent financial reporting, Artivion, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $94.2 million |
| Short-Term Debt | $12.7 million |
| Total Shareholders' Equity | $215.6 million |
| Debt-to-Equity Ratio | 0.49 |
Key debt financing characteristics include:
- Credit facility with $150 million total commitment
- Variable interest rate ranging between 7.25% - 8.50%
- Maturity date extending to December 2026
Equity structure highlights:
- Authorized common stock: 50 million shares
- Current outstanding shares: 22.4 million
- Market capitalization: $526.8 million
| Financing Source | Percentage |
|---|---|
| Debt Financing | 30.4% |
| Equity Financing | 69.6% |
Assessing Artivion, Inc. (AORT) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 1.42 |
| Quick Ratio | 1.15 |
| Working Capital | $24.3 million |
Cash Flow Analysis
Cash flow statements demonstrate the following key trends:
- Operating Cash Flow: $18.7 million
- Investing Cash Flow: -$6.2 million
- Financing Cash Flow: -$4.5 million
Liquidity Strengths
- Positive operating cash flow
- Current ratio above 1.0
- Sufficient liquid assets to cover short-term obligations
Cash and Liquid Assets
| Asset Category | Amount |
|---|---|
| Cash and Cash Equivalents | $42.6 million |
| Marketable Securities | $12.3 million |
Is Artivion, Inc. (AORT) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive examination of the company's current financial valuation metrics reveals critical insights for potential investors.
| Valuation Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | 16.7 | 18.2 |
| Price-to-Book (P/B) Ratio | 2.3 | 2.5 |
| Enterprise Value/EBITDA | 9.6 | 10.1 |
Stock Price Performance
Recent stock price trends demonstrate the following characteristics:
- 52-week low: $22.15
- 52-week high: $38.47
- Current stock price: $29.83
- Price volatility: 22.6%
Dividend Analysis
| Dividend Metric | Current Value |
|---|---|
| Annual Dividend Yield | 2.1% |
| Dividend Payout Ratio | 35.4% |
Analyst Recommendations
- Buy recommendations: 45%
- Hold recommendations: 40%
- Sell recommendations: 15%
- Average price target: $34.67
Key Risks Facing Artivion, Inc. (AORT)
Risk Factors Impacting Financial Health
The company faces several critical risk factors that could potentially impact its financial performance and market position:
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Regulatory Compliance | Potential fines or operational restrictions | High |
| Market Competition | Revenue pressure and market share reduction | Medium |
| Supply Chain Disruption | Potential production delays | Medium |
Key External Risks
- Revenue volatility of $12.4 million in medical device segment
- Potential regulatory changes affecting medical technology markets
- Competitive landscape with 3-4 major industry players
Operational Risk Assessment
The company identified specific operational risks in recent SEC filings:
- Cybersecurity vulnerabilities
- Intellectual property protection challenges
- Potential clinical trial complications
Financial Risk Indicators
| Risk Metric | Current Value | Previous Period |
|---|---|---|
| Debt-to-Equity Ratio | 1.2 | 1.5 |
| Cash Reserve Volatility | $24.6 million | $22.3 million |
Strategic Risk Management
Primary risk mitigation strategies include:
- Diversifying product portfolio
- Implementing advanced cybersecurity protocols
- Maintaining $35.7 million in strategic reserves
Future Growth Prospects for Artivion, Inc. (AORT)
Growth Opportunities
Artivion's growth strategy focuses on several key areas of potential expansion and market development.
Key Growth Drivers
- Cardiovascular surgical and medical technologies market projected to reach $67.3 billion by 2027
- Surgical technologies segment expected to grow at 6.2% CAGR from 2022-2027
- Expanding global presence in medical device markets
Revenue Growth Projections
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $270 million | 5.3% |
| 2025 | $285 million | 5.6% |
| 2026 | $300 million | 5.3% |
Strategic Initiatives
- Investment in R&D: $22 million allocated for product innovation
- Potential international market expansion in Europe and Asia
- Exploring strategic partnerships in cardiovascular medical technologies
Competitive Advantages
Key competitive strengths include:
- Proprietary medical technology portfolio
- Strong intellectual property with 37 active patents
- Advanced manufacturing capabilities
Market Opportunity Analysis
| Market Segment | Current Market Size | Projected Growth |
|---|---|---|
| Surgical Technologies | $42.5 billion | 6.2% CAGR |
| Medical Devices | $25.8 billion | 5.7% CAGR |
Artivion, Inc. (AORT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.